NCT07279740: Methylphenidate + tDCS for AD

NCT07279740: Methylphenidate + tDCS for Alzheimer's Disease

Overview

This clinical trial investigates the combined effects of transcranial direct current stimulation (tDCS) and methylphenidate for treating cognitive dysfunction in [Alzheimer's disease](/diseases/alzheimers-disease). The trial is being conducted at Mayo Clinic and represents an innovative approach combining non-invasive brain stimulation with pharmacological enhancement to potentially improve cognitive outcomes beyond either treatment alone.

NCT07279740: Methylphenidate + tDCS for Alzheimer's Disease

Overview

This clinical trial investigates the combined effects of transcranial direct current stimulation (tDCS) and methylphenidate for treating cognitive dysfunction in [Alzheimer's disease](/diseases/alzheimers-disease). The trial is being conducted at Mayo Clinic and represents an innovative approach combining non-invasive brain stimulation with pharmacological enhancement to potentially improve cognitive outcomes beyond either treatment alone.

The rationale for this combination approach stems from the understanding that both tDCS and methylphenidate can enhance cognitive function through different but potentially complementary mechanisms: tDCS modulates cortical excitability and neuroplasticity, while methylphenidate increases synaptic dopamine and norepinephrine availability["@tdcs2023"].

Trial Information

| Field | Value |
|-------|-------|
| Trial ID | NCT07279740 |
| Phase | Phase 2 |
| Status | Recruiting |
| Location | Mayo Clinic (US) |
| Sponsor | Mayo Clinic |
| Participants | 12 |
| Study Design | Interventional, single-arm |

Mechanism of Action

Transcranial Direct Current Stimulation (tDCS)

tDCS is a non-invasive brain stimulation technique that uses low-intensity direct current to modulate neuronal excitability[@nitsche2008]:

Physical Parameters:

• Current intensity: 1-2 mA
• Electrode placement: Anode (excitatory) over target region
• Session duration: 20-30 minutes
• Number of sessions: Multiple (typically 5-20)

• Anodal tDCS: Increases cortical excitability
• Cathodal tDCS: Decreases cortical excitability

• Modulates long-term potentiation (LTP)-like processes
• Alters NMDA receptor activity
• Affects GABAergic signaling

• Modulates functional connectivity
• May enhance memory circuits

Typically, tDCS in AD targets:

• Left dorsolateral prefrontal cortex (DLPFC): Attention and executive function
• Temporal-parietal regions: Memory and language
• Left inferior parietal lobule: Semantic memory

Methylphenidate Pharmacology

Methylphenidate (Ritalin®, Concerta®) is a psychostimulant that increases dopamine and norepinephrine availability[@methylphenidate2022]:

Mechanism of Action:

• Dopamine reuptake inhibition: Blocks dopamine transporter (DAT)
• Norepinephrine reuptake inhibition: Blocks norepinephrine transporter (NET)
• Indirect agonist effect: Increases extracellular dopamine and norepinephrine

• Enhanced attention and alertness
• Improved executive function
• Working memory improvement
• Reduced psychomotor retardation

• Addresses catecholaminergic deficit in AD
• May enhance motivation and engagement
• Potential to improve response to cognitive training

Combination Hypothesis

The combination of tDCS with methylphenidate may provide synergistic benefits:

Scientific Rationale

tDCS for Alzheimer's Disease

Evidence supports tDCS benefits in AD[@lefaucheur2017]:

Cognitive Outcomes:

• Improved memory encoding and retrieval
• Enhanced attention and working memory
• Reduced naming deficits
• Benefits in mild-to-moderate AD

• Increased cerebral blood flow
• Enhanced functional connectivity
• Modulation of default mode network

• Generally well-tolerated
• Minimal side effects
• Suitable for elderly populations

Methylphenidate in Neurodegeneration

Methylphenidate has been studied in various cognitive disorders:

AD-Specific Evidence:

• Improves apathy in some patients
• May enhance cognitive engagement
• Limited but promising data

• Cardiovascular monitoring needed
• Potential for sleep disturbance
• Risk of agitation in some patients

Rationale for Combination

The theoretical basis for combination:

Trial Design

Study Protocol

Intervention Schema:

• tDCS sessions over defined period
• Concurrent or prior methylphenidate administration
• Cognitive assessments pre/post intervention

Outcome Measures

Primary Endpoints:

• Safety and tolerability
• Cognitive function (cognitive batteries)

• Memory performance
• Attention and executive function
• Quality of life measures

Patient Population

Inclusion Criteria

• Clinical diagnosis of Alzheimer's disease
• MMSE score in mild-to-moderate range
• Stable medications
• Ability to comply with tDCS sessions
• Capacity to consent or proxy consent

Exclusion Criteria

• Contraindications to tDCS (metal implants, seizures)
• Significant cardiac disease
• Active psychosis
• Methylphenidate contraindication

Clinical Significance

Potential Benefits

If successful, this trial could establish:

Challenges

• Small sample size limits generalizability
• Optimal combination parameters unknown
• Individual response variability

Future Directions

Results may inform:

• Larger Phase 2/3 trials
• Optimal stimulation parameters
• Biomarker predictors of response

Safety Profile

tDCS Safety

| Adverse Event | Frequency |
|---------------|-----------|
| Skin irritation | 1-10% |
| Headache | 1-5% |
| Tingling sensation | Common (transient) |
| Fatigue | Rare |

Methylphenidate Safety

| Adverse Event | Frequency |
|---------------|-----------|
| Appetite loss | 10-30% |
| Sleep disturbance | 10-20% |
| Headache | 5-15% |
| Mood changes | 5-10% |

Related Mechanisms

Neuroplasticity Enhancement

• Long-term potentiation (LTP)
• Synaptic strengthening
• Network reorganization

Catecholaminergic Signaling

• Dopamine pathways in cognition
• Norepinephrine and attention
• Mesocortical and mesolimbic systems

Cortical Excitability

• Membrane polarization effects
• NMDA receptor modulation
• GABAergic changes

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Transcranial Direct Current Stimulation](/therapeutics/tdcs)
• [Methylphenidate](/therapeutics/methylphenidate)
• [Cognitive Enhancement](/mechanisms/cognitive-enhancement)
• [Brain Stimulation Therapies](/therapeutics/brain-stimulation-therapies)

External Links

• [ClinicalTrials.gov - NCT07279740](https://clinicaltrials.gov/study/NCT07279740)
• [Mayo Clinic](https://www.mayoclinic.org/)
• [PubMed - tDCS in AD](https://pubmed.ncbi.nlm.nih.gov/37245678/)

References